用[11C]氟马西尼PET显像胰腺胰岛GABAA受体
本研究以猪、小鼠及人胰腺组织评估[11C]氟马西尼([11C]FMZ)作为胰腺内分泌细胞质量PET标志物的可行性。猪体内PET/CT显示胰腺摄取中等且仅部分被阻断,体外实验显示胰岛结合弱且变异大。作者认为[11C]FMZ与胰岛GABAA受体结合但对比度和幅度不足,尚不能作为胰腺内分泌质量的体内PET标志物。
要点
- 猪体内[11C]FMZ胰腺摄取中等,仅部分被未标记氟马西尼阻断。
- 体外实验中[11C]FMZ在胰岛的结合弱且变异大。
- 作者认为[11C]FMZ对比度和幅度不足,尚不能作为体内PET标志物。
核心结论
- 作者认为[11C]FMZ与胰岛GABAA受体结合,但对比度或幅度不足,尚不能作为胰腺内分泌质量的体内PET标志物。
- 作者认为GABAA受体仍可能是胰腺内分泌细胞的潜在显像靶点,但需要针对单个GABAA受体亚型具有更高亲和力和选择性的示踪剂。
研究设计与样本
- 猪胰腺体内[11C]FMZ PET/CT显像,分别行示踪剂单独注射及未标记氟马西尼阻断GABAA受体后显像。
- 体外实验采用猪胰腺及人器官供者胰腺冷冻切片、分离的小鼠和人胰岛及外分泌组织制备。
- 用免疫组化探索猪、人、小鼠胰腺中GABAA受体亚型的表达。
主要发现
- 猪脑可见强烈的特异性[11C]FMZ体内摄取,而胰腺信号中等且仅部分被阻断。
- 体外实验中,小鼠、猪和人胰腺胰岛与[11C]FMZ的结合较外分泌组织为阳性但弱且变异大。
- 猪和小鼠胰岛中鉴定出GABAA受体β2和γ2亚型,未鉴定出α2亚型。
- 非糖尿病供者人胰腺中鉴定出α2、β2(弱)和γ2亚型,而一例2型糖尿病供者中α2亚型缺失。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Type 1 diabetes (T1D) is an autoimmune disease characterized by a progressive β-cell destruction. There are no clinically established methods for quantifying endocrine cells of the pancreas and current knowledge is almost exclusively based on autopsy material and functional measurements. Based on the expression of the γ-aminobutyric acid A receptors (GABAARs) in pancreatic islets and the fact that GABAAR agonists are being explored as treatment for T1D, we hypothesized that the positron emission tomography (PET) tracer [11C]flumazenil ([11C]FMZ) could serve as a marker of the endocrine mass of the pancreas. The in vivo uptake of [11C]FMZ in pig pancreas was evaluated by PET/CT, either tracer alone or after blockade of GABAAR by unlabeled flumazenil. The pancreatic binding of [11C]FMZ was investigated in vitro with frozen sections of pig pancreas as well as human organ donors, in addition to isolated mouse and human islets and exocrine preparations. The expression of GABAAR subunits in pig, human and mouse pancreas was explored by immunohistochemistry. RESULTS: Strong specific in vivo uptake of [11C]FMZ was observed in the pig brain as expected, but in the pancreas the signal was moderate and only partially reduced by blockade. In vitro experiments revealed a positive but weak and variable binding of [11C]FMZ in islets compared to exocrine tissue in the mouse, pig and human pancreas. In pig and mouse pancreatic islets we identified the GABAAR subunits β2 and γ2 but not α2. In the human pancreas from non-diabetic donors, we have identified the α2, β2 (although weak) and γ2 subunits, whereas from a T2D donor the α2 subunit was missing. CONCLUSIONS: Our findings suggest that [11C]FMZ bind to GABAARs in the islets, but not with a sufficient contrast or magnitude to be implemented as an in vivo PET marker for the endocrine mass of the pancreas. However, GABAARs with different subunits are widely expressed in the endocrine cells within the pancreas in pig, human and mouse. Hence, the GABAAR could still be a potential imaging target for the endocrine cells of the pancreas but would require tracers with higher affinity and selectivity for individual GABAAR subunits.
引用
- Maloum-Rami F, Cheung P, Antoni G, et al. PET imaging of GABAA receptors in pancreatic islets by [11C]flumazenil. EJNMMI Res. 2024. PMID: 39623212. doi:10.1186/s13550-024-01176-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。